Potential repositioning of exemestane as a neuroprotective agent for Parkinson’s disease

References

• Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol 2013;22:11–17.
   PubMedGoogle Scholar
• Lull ME, Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics 2010;7:354–365.
   PubMed Web of Science ®Google Scholar
• Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 2004;36:1199–1207.
   PubMed Web of Science ®Google Scholar
• Innamorato NG, Rojo AI, Garcia-Yague AJ, Yamamoto M, de Ceballos ML, Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 2008;181:680–689.
   PubMed Web of Science ®Google Scholar
• Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010;58:588–598.
   PubMed Web of Science ®Google Scholar
• Woo SY, Kim JH, Moon MK, Han S-H, Yeon SK, Choi JW, et al. Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy. J Med Chem 2014;57:1473–1487.
   PubMed Web of Science ®Google Scholar
• Lee JA, Kim JH, Woo SY, Son HJ, Han SH, Jang BK, et al. A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson's disease animal model. Br J Pharmacol 2015;172:1087–1100.
   PubMed Web of Science ®Google Scholar
• Lee JA, Son HJ, Park KD, Han SH, Shin N, Kim JH, et al. A novel compound ITC-3 activates the Nrf2 signaling and provides neuroprotection in Parkinson's disease models. Neurotox Res 2015;28:332–345.
   PubMed Web of Science ®Google Scholar
• Son HJ, Choi JH, Lee JA, Kim DJ, Shin KJ, Hwang O. Induction of NQO1 and neuroprotection by a novel compound KMS04014 in Parkinson's Disease Models. J Mol Neurosci 2015;56:263–272.
   PubMed Web of Science ®Google Scholar
• Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, et al. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 2009;4:e5757.
   PubMed Web of Science ®Google Scholar
• Trinh K, Andrews L, Krause J, Hanak T, Lee D, Gelb M, Pallanck L. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism. J Neurosci 2010;30:5525–5532.
   PubMed Web of Science ®Google Scholar
• Jakel RJ, Townsend JA, Kraft AD, Johnson JA. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 2007;1144:192–201.
   PubMed Web of Science ®Google Scholar
• Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci USA 2009;106:2933–2938.
   PubMed Web of Science ®Google Scholar
• Innamorato NG, Jazwa A, Rojo AI, García C, Fernández-Ruiz J, Grochot-Przeczek A, et al. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 2010;5:e11838.
   PubMed Web of Science ®Google Scholar
• Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, Rábano A, Kirik D, Cuadrado A. Alpha-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum Mol Genet 2012;21:3173–3192.
   PubMed Web of Science ®Google Scholar
• Bove J, Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 2012;211:51–76.
   PubMed Web of Science ®Google Scholar
• McDowell K, Chesselet MF. Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis 2012;46:597–606.
   PubMed Web of Science ®Google Scholar
• Hisahara S, Shimohama S. Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis 2010;2011:951709.
   PubMedGoogle Scholar
• Son HJ, Lee JA, Shin N, Choi JH, Seo JW, Chi DY, et al. A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP. Br J Pharmacol 2012;165:2213–2227.
   PubMed Web of Science ®Google Scholar
• Hara H, Ohta M, Adachi T. Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J Neurosci Res 2006;84:860–866.
   PubMed Web of Science ®Google Scholar
• Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego (CA): Academic Press; 1997:59−67.
   Google Scholar
• Kim ST, Son HJ, Choi JH, Ji IJ, Hwang O. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease. Brain Res 2010;1306:176–183.
   PubMed Web of Science ®Google Scholar
• Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 2003;23:8137–8151.
   PubMed Web of Science ®Google Scholar
• van Muiswinkel FL, de Vos RA, Bol JG, Andringa G, Jansen Steur ENH, Ross D, et al. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 2004;25:1253–1262.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Kim SW, Lee SY, Hwang O. Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem 2003;86:143–152.
   PubMed Web of Science ®Google Scholar
• Lee SY, Moon Y, Hee Choi D, Jin Choi H, Hwang O. Particular vulnerability of rat mesencephalic dopaminergic neurons to tetrahydrobiopterin: relevance to Parkinson's disease. Neurobiol Dis 2007;25:112–120.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381–2391.
   PubMed Web of Science ®Google Scholar
• Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 1988;30:391–394.
   PubMedGoogle Scholar
• Dinkova-Kostova AT, Talalay P, Sharkey J, Zhang Y, Holtzclaw WD, Wang XJ, et al. An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1. J Biol Chem 2010;285:33747–33755.
   PubMed Web of Science ®Google Scholar
• Lu KT, Ko MC, Chen BY, Huang J-C, Hsieh C-W, Lee M-C, et al. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chem 2008;56:6910–6913.
   PubMed Web of Science ®Google Scholar
• Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental Parkinsonism. Antioxid Redox Signal 2011;14:2347–2360.
   PubMed Web of Science ®Google Scholar
• Bains M, Roberts JL. Estrogen protects against dopamine neuron toxicity in primary mesencephalic cultures through an indirect P13K/Akt mediated astrocyte pathway. Neurosci Lett 2015;610:79–85.
   PubMed Web of Science ®Google Scholar
• Liu H, Talalay P. Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention. Proc Natl Acad Sci USA 2013;110:19065–19070.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285–1291.
   PubMed Web of Science ®Google Scholar
• Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994;165:208–210.
   PubMed Web of Science ®Google Scholar
• Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995;202:17–20.
   PubMed Web of Science ®Google Scholar
• Qureshi GA, Baig S, Bednar I, Södersten P, Forsberg G, Siden A. Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Neuroreport 1995;6:1642–1644.
   PubMed Web of Science ®Google Scholar
• Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403–1409.
   PubMed Web of Science ®Google Scholar
• Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000;74:2213–2216.
   PubMed Web of Science ®Google Scholar
• Xing B, Xin T, Hunter RL, Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation 2008;5:4.
   PubMed Web of Science ®Google Scholar
• Ferger B, Leng A, Mura A, Hengerer B, Feldon J. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 2004;89:822–833.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Ishii A, Ohtaki H, Shioda S, Yoshida T, Numazawa S. Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice. J Neuroinflammation 2013;10:143.
   PubMed Web of Science ®Google Scholar
• Tufekci KU, Civi Bayin E, Genc S, Genc K. The Nrf2/ARE Pathway: a promising target to counteract mitochondrial dysfunction in Parkinson's disease. Parkinsons Dis 2011;2011:314082.
   PubMedGoogle Scholar
• Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000;129:77–97.
   PubMed Web of Science ®Google Scholar
• Zafar KS, Inayat-Hussain SH, Siegel D, Bao A, Shieh B, Ross D. Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. Toxicol Lett 2006;166:261–267.
   PubMed Web of Science ®Google Scholar
• van Muiswinkel FL, Kuiperij HB. The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. CDTCNSND 2005;4:267–281.
   Google Scholar
• Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 1998;71:2112–2122.
   PubMed Web of Science ®Google Scholar
• Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 2010;50:323–354.
   PubMed Web of Science ®Google Scholar
• Vile GF, Basu-Modak S, Waltner C, Tyrrell RM. Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc Natl Acad Sci USA 1994;91:2607–2610.
   PubMed Web of Science ®Google Scholar
• Hung SY, Liou HC, Kang KH, Wu R-M, Wen C-C, Fu W-M. Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridinium-induced neurotoxicity. Mol Pharmacol 2008;74:1564–1575.
   PubMed Web of Science ®Google Scholar
• Blesa J, Juri C, García-Cabezas MÁ, Adánez R, Sánchez-González MÁ, Cavada C, Obeso JA. Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson's disease. Front Syst Neurosci 2011;5:92.
   PubMedGoogle Scholar
• Poulin JF, Zou J, Drouin-Ouellet J, Kim YA, Cicchetti F, Awatramani RB. Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling. Cell Rep 2014;9:930–943.
   PubMed Web of Science ®Google Scholar
• Blesa J, Juri C, Collantes M, Peñuelas I, Prieto E, Iglesias E, et al. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study. Neurobiol Dis 2010;38:456–463.
   PubMed Web of Science ®Google Scholar
• Taylor TN, Greene JG, Miller GW. Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res 2010;211:1–10.
   PubMed Web of Science ®Google Scholar
• Johnson DA, Johnson JA. Nrf2—a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med 2015;88:253–267.
   PubMed Web of Science ®Google Scholar
• Silva-Palacios A, Königsberg M, Zazueta C. Nrf2 signaling and redox homeostasis in the aging heart: a potential target to prevent cardiovascular diseases? Ageing Res Rev 2016;26:81–95.
   PubMed Web of Science ®Google Scholar
• Jiménez-Osorio AS, González-Reyes S, Pedraza-Chaverri J. Natural Nrf2 activators in diabetes. Clin Chim Acta 2015;448:182–192.
   PubMed Web of Science ®Google Scholar
• Reinisalo M, Kårlund A, Koskela A, Kaarniranta K, Karjalainen RO. Polyphenol stilbenes: molecular mechanisms of defence against oxidative stress and aging-related diseases. Oxid Med Cell Longev 2015:2015:340520.
   PubMed Web of Science ®Google Scholar
• Fadiran EM, Duan J. Aromasin (Exemestane). Clinical pharmacology and biopharmaceutics review. Center for Drug Evaluation and Research, U.S. Food and Drug Administration; 1999. App # NDA 20753.
   Google Scholar